Celgene Expands Relationship with Medidata in Enterprise Clinical Trial Technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Needham & Company Remains Bullish on Medidata Solutions (MDSO) Despite Revenue Shortfall
February 11, 2016 8:35 AM ESTNeedham & Company maintained a Buy rating on Medidata Solutions (NASDAQ: MDSO), and cut the price target to $45.00 (from $65.00), following the company's 4Q earnings report. Despite MDSO's reported revenue shortfall (missed Street estimates by $6MM), Needham would characterize leading indicators as somewhat encouraging. Needham analysts... More
Medidata Solutions (MDSO) Tops Q4 EPS by 3c
February 10, 2016 6:35 AM ESTMedidata Solutions (NASDAQ: MDSO) reported Q4 EPS of $0.27, $0.03 better than the analyst estimate of $0.24. Revenue for the quarter came in at $98.9 million versus the consensus estimate of $105.09 million.
GUIDANCE:
Medidata Solutions sees FY2016 revenue of $450-474 million, versus the consensus of... More
